Parkinson’s disease treatments associated with compulsive behaviors

	Tweet

Pathological gambling, compulsive shopping, binge eating and other impulse control disorders appear to be more common among individuals taking dopamine agonist medications for Parkinson’s disease, according to a report in the May issue of Archives of Neurology, one of the JAMA/Archives journals.

These behaviors have been reported previously in patients with Parkinson’s disease, according to background information in the article. Preliminary estimates of impulse control disorders in this population range from 1.7 percent to 6.1 percent for gambling, 2 percent to 4 percent for compulsive sexual behavior and 0.4 percent to 3 percent for compulsive buying.

Daniel Weintraub, M.D., of the University of Pennsylvania, Philadelphia, and Philadelphia Veterans Affairs Medical Center, and colleagues studied 3,090 patients being treated for Parkinson’s disease at 46 movement disorder centers in the United States and Canada. 

Impulse control disorders were identified in 13.6 percent of patients, including gambling in 5 percent, compulsive sexual behavior in 3.5 percent, compulsive buying in 5.7 percent, binge-eating disorder in 4.3 percent and two or more of those in 3.9 percent. The disorders were more common in individuals taking dopamine agonists compared with patients not taking dopamine agonists (17.1 percent vs. 6.9 percent).

Additional variables that were associated with these disorders included the use of levodopa, another therapy for Parkinson’s disease; living in the United States; being younger or unmarried; smoking cigarettes; and having a family history of gambling problems.

“Dopamine agonist treatment in Parkinson’s disease is associated with 2- to 3.5-fold increased odds of having an impulse control disorder,” the authors write. “This association represents a drug class relationship across impulse control disorders. The association of other demographic and clinical variables with impulse control disorders suggests a complex relationship that requires additional investigation to optimize prevention and treatment strategies.”

Dopamine agonists are increasingly used to treat other conditions, including restless legs syndrome and fibromyalgia, the authors note. “Larger epidemiologic studies in these other populations are needed to examine the possible relationships between dopamine agonist treatment, other clinical features and impulse control disorders,” they conclude.

###

(Arch Neurol. 2010;67[5]:589-595. Available pre-embargo to the media at http://www.jamamedia.org.)

Editor’s Note: This study, the DOMINION Study, was funded by Boehringer Ingelheim and designed jointly by Boehringer Ingelheim and the Scientific Advisory Board. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

---

Contact: Kim Guenther

215-662-6183
JAMA and Archives Journals

RELATED STORIES:
Treating carotid blockage may reverse dementia   Treating Depression Often Requires Trying Different Drugs   Women with depression risk relapse while pregnant   Depression rife among medical students   Cognitive Therapy Successful Against Depression   TV ratings for kid shows get failing grade   United States Sees Highest Suicide Rate in 15 Years   Psychiatric disorders and behavioral characteristics of pediatric patients with both epilepsy   Creative Strategies Improve Medical Care for Mentally Ill   Task Force Recommends Screening Adolescents for Clinical Depression   Social support may stave off depression in women   Heavy pot smoking may trigger psychosis: study   New links between cholesterol and depression in the elderly   Physicians Should Help Patients with Depression Name Their Problem   Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]